Search

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Jun 14 2013

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

Jun 13 2014 Posted in Press releases

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Highlights from the SWG

SWG Session at EHA2023ELN-EHA SWG for CML: CML: modelling the futureChairJane Apperley (United Kingdom)

Topics and presenters
Identifying new targets for BCR::ABL1 inhibition: Oliver Hantschel (Germany). Dissecting phylogenetic trees in CML: Aleksandra Kamizela (United Kingdom).

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Jun 10 2016 Posted in Press releases

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Jun 12 2015 Posted in Press releases

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Highlights from the SWG

SWG AML Annual Scientific MeetingThe most recent SWG AML Annual Scientific Meeting took place during the annual EHA Congress in Frankfurt, Germany.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.